Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion

mBio, Journal Year: 2024, Volume and Issue: 15(5)

Published: April 9, 2024

The rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted comprehensive investigation into two newly emerged variants, BA.2.87.1 and JN.1, focusing on their neutralization resistance, infectivity, antigenicity, cell-cell fusion, spike processing. Neutralizing antibody (nAb) titers were assessed in diverse cohorts, including individuals who received bivalent mRNA vaccine booster, patients infected during BA.2.86/JN.1-wave, hamsters vaccinated with XBB.1.5-monovalent vaccine. We found that shows much less nAb escape from WT-BA.4/5 JN.1-wave breakthrough infection sera compared JN.1 XBB.1.5. Interestingly, is more resistant by XBB.1.5-monovalent-vaccinated hamster than BA.2.86/JN.1 XBB.1.5, but efficiently neutralized class III monoclonal S309, which largely fails neutralize BA.2.86/JN.1. Importantly, exhibits higher levels fusion activity, furin cleavage efficiency Antigenically, closer ancestral BA.2 other recently Omicron subvariants Altogether, these results highlight immune properties as well biology new underscore importance continuous surveillance informed decision-making development effective vaccines.

Language: Английский

---

Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1

Vaccine, Journal Year: 2024, Volume and Issue: 42(9), P. 2117 - 2121

Published: March 7, 2024

A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple are located N-terminal domain (NTD) rather than receptor binding (RBD) of protein. We evaluated neutralizing antibody (NAb) responses to because its sequence unique NTD region. Our data show that NAb were lower BA.2 but higher JN.1, suggesting is not a further escape variant other currently circulating Moreover, XBB.1.5 mRNA boosting increased titers all variants tested including BA.2.87.1.

Language: Английский

---

The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: July 29, 2024

The JN.1 variant of COVID-19 has emerged as the dominant strain worldwide since end 2023. As a subclade BA.2.86 variant, harbors unique combination mutations inherited from lineage, notably featuring novel L455S mutation within its receptor-binding motif. This been linked to increased transmissibility and enhanced immune evasion capabilities. During rise JN.1, evidence resistance various monoclonal antibodies reduced cross-neutralization effects XBB.1.5 vaccine have observed. Although public health threat posed by appears relatively low, concerns persist regarding evolutionary trajectory under pressure. review provides comprehensive overview evolving highlighting need for continuous monitoring investigation new variants that could lead widespread infection. It assesses efficacy current vaccines therapeutics against emerging variants, particularly focusing on immunocompromised populations. Additionally, this summarizes potential advancements clinical treatments COVID-19, offering insights optimize prevention treatment strategies. thoroughly evaluates variant's impact implications future therapeutic development, contributing ongoing efforts mitigate risk virus transmission disease severity.

Language: Английский

---

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: April 15, 2024

The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible XBB-induced humoral immunity compared JN.1. Notably, lacks critical escaping in receptor binding domain (RBD) thus allowing various classes neutralizing antibodies (NAbs) were escaped by XBB or BA.2.86 subvariants neutralize although deletions N-terminal (NTD), specifically 15-23del 136-146del, compensate for resistance immunity. Interestingly, several antibody drugs have been found restore their efficacy against including SA58, REGN-10933 COV2-2196. Hence, our results suggest may not become widespread until it acquires multiple RBD achieve sufficient comparable

Language: Английский

---

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 8, 2024

Abstract The recent emergence of a SARS-CoV-2 saltation variant, BA.2.87.1, which features 65 spike mutations relative to BA.2, has attracted worldwide attention. In this study, we elucidate the antigenic characteristics and immune evasion capability BA.2.87.1. Our findings reveal that BA.2.87.1 is more susceptible XBB-induced humoral immunity compared JN.1. Notably, lacks critical escaping in receptor binding domain (RBD) thus allowing various classes neutralizing antibodies (NAbs) were escaped by XBB or BA.2.86 subvariants neutralize although deletions N-terminal (NTD), specifically 15-23del 136-146del, compensate for resistance immunity. Interestingly, several antibody drugs have been found restore their efficacy against including SA58, REGN-10933 COV2-2196. Hence, our results suggest may not become widespread until it acquires multiple RBD achieve sufficient comparable

Language: Английский

---

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 11, 2024

Abstract As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory understanding functional consequences of its mutations remain crucial. Here, we characterized antibody evasion, ACE2 receptor engagement, infectivity highly mutated Omicron subvariant BA.2.87.1. Compared with other subvariants, including EG.5.1 current predominant JN.1, BA.2.87.1 exhibits less immune reduced comparable in Calu-3 lung cells. Intriguingly, two large deletions (Δ15-26 Δ136-146) N-terminal domain (NTD) spike protein facilitate subtly increased evasion but significantly diminish infectivity. Collectively, our data support announcement by USA CDC that public health risk posed appears be low.

Language: Английский

---